ECDC and the European Respiratory Society (ERS) have developed 21 patient-centred standards that aim to guide clinicians and public health workers in their daily work to ensure optimal diagnosis, treatment and prevention of tuberculosis (TB) in Europe. Nearly 74 000 reported TB cases in the EU/EEA in 2010 clearly show that tuberculosis remains a public health challenge across the region.
This study found a marked reduction in vaccine serotype carriage after PCV7 implementation. The overall pneumococcal, H. influenzae and S. aureus carriage decreased slightly, but not significantly.
This study, strong of an almost complete follow-up of all children born in Denmark from 2003 to 2008, provides evidence that the DTaP-IPV-HiB vaccine is not associated to an overall increased risk of febrile seizures and epilepsy.
To mark World Tuberculosis Day on 24 March 2012, the European Centre for Disease Prevention and Control (ECDC) and the WHO Regional Office for Europe publish their joint report, Tuberculosis surveillance and monitoring in Europe 2012.
This study demonstrates that PCV13 is immunogenic and safe in children previously vaccinated with PCV7. By eliciting high antibacterial immune responses to the additional serotypes, PCV13 provides protection against these serotypes, which are important causes of pneumococcal disease globally.
The evidence presented in the article strongly supports the notion that serotype replacement has occurred in invasive pneumococcal disease in most populations and is caused by the vaccine.
Clostridium difficile infection is the leading cause of healthcare-associated diarrhoea in the developed world and represents a major financial burden for European healthcare systems.
Patient transfer between hospitals and in particular between countries, is a risk factor for the spread of bacteria that are resistant to last-line antibiotics. More specifically, for highly resistant bacteria, like carbapenamase-producing Enterobacteriaceae (CPE), the risk is heightened when patients are transferred from, or have received previous medical care in areas with high rates of bacterial resistance. These are conclusions from a risk assessment produced by ECDC that evaluated the risk to the citizens of Europe, of the spread of CPE through patient transfer between healthcare facilities, with special emphasis on cross-border transfer.
ECDC West Nile fever maps are based on information provided by the health authorities across Europe with the objective to inform the national competent authorities about WNV affected areas.